The Latest Cardiac and Vascular News
Use of artificial intelligence technology efficiently identifies eligible patient candidates for pivotal clinical trial; program launched at The Christ Health Network SANTA CLARA, Calif. & ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a medical device company developing a novel transcatheter device-based therapy to address heart failure (HF), and egnite, Inc., a leading digital health […]
– Performance-Based Agreement Provides for Currax’s 72 Sales Representatives to Detail Esperion’s Products – – Reinforces Esperion’s Focus on Driving Persistent Growth By More Than Doubling Sales Team – ANN ARBOR, Mich., April 19, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced an agreement with Currax Pharmaceuticals LLC that provides for all of […]
Non-invasive, AI-enabled product helps CT readers to accurately*, efficiently, and consistently identify narrowings in the coronary arteries, advancing the HeartFlow portfolio MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) — HeartFlow, Inc. today announced the launch of the RoadMap analysis, a new AI-enabled product that assists CT readers to accurately*, […]
Hoag is one of the first three sites in the nation enrolling patients in a post-market study Hoag cardiac surgeons are among an elite class of specialists experienced with this latest generation valve option Study expected to grow to include centers around the world NEWPORT BEACH, Calif., April 17, 2023 /PRNewswire/ — […]
Compounds that activate SERCA2a may lead to novel therapies for heart failure WARRINGTON, Pa., April 17, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the European Patent Office has granted Patent […]
HOUSTON–(BUSINESS WIRE)–IPS HEART has been granted rare pediatric drug designation by the FDA for GIVI-MPC, a first-in-class stem cell therapeutic to create new skeletal muscle with 100% full length dystrophin and for ISX9-CPC, a first-in-class stem cell therapeutic for creating new functional cardiac muscle for the treatment of patients with Duchenne […]
WASHINGTON, April 11, 2023 /PRNewswire/ — A first-of-its-kind study has established pediatric reference intervals for two common tests for cardiovascular disease. Published in AACC’s The Journal of Applied Laboratory Medicine, these findings are crucial to advancing diagnosis and treatment of heart conditions in children. View the full study here: https://doi.org/10.1093/jalm/jfad012 Many pediatric hospitals have started […]
VANCOUVER, Wash., April 12, 2023 /PRNewswire/ — Evermed and the American College of Cardiology (ACC) have announced the launch of ACC Anywhere, a new content hub that provides cardiologists around the world with on-demand access to the latest clinical knowledge. The hub contains original content from five conferences including ACC’s 2022 and […]
WAKEFIELD, Mass., April 12, 2023 /PRNewswire/ — Ablative Solutions, Inc., a company pioneering new approaches to the treatment of hypertension, today announced the completion of patient enrollment in the TARGET BP I Pivotal Study evaluating alcohol-mediated renal denervation with the Peregrine System. “We are pleased to announce this significant milestone”, stated Kate Rumrill, […]
Company to prioritize the clinical development of TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030 Strategic decision based upon this significant unmet […]
